Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,188.43 +7.69 (+0.15%) Dow
38,965.37 +113.10 (+0.29%) Nasdaq
16,337.00 -12.25 (-0.07%) Bitcoin USD
63,294.63 -861.49 (-1.34%) CMC Crypto 200
1,313.51 -51.62 (-3.78%)
Intra-Cellular Therapies, Inc. (ITCI)
| Previous close | 71.01 |
| Open | 69.72 |
| Bid | 50.81 x 200 |
| Ask | 89.07 x 200 |
| Day's range | 68.61 - 70.77 |
| 52-week range | 45.50 - 84.89 |
| Volume | |
| Avg. volume | 975,177 |
| Market cap | 7.356B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.46 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 91.91 |
- GuruFocus.com
Intra-Cellular Therapies Surpasses Q1 Revenue Estimates with Strong CAPLYTA Sales
Robust Growth and Positive Clinical Results Propel Forward Momentum
ZacksIntra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 48.39% and 2.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireIntra-Cellular Therapies Reports First Quarter 2024 Financial Results
CAPLYTA Q1 2024 net product sales were $144.8 million, compared to $94.7 million for the same period in 2023, representing a 53% increase CAPLYTA’s strong prescription uptake continues: Q1 2024 CAPLYTA total prescriptions increased 39%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance reiterated at $645 - $675 million Announced robust positive Phase 3 results from Study 501 evaluating lumateperone as an adjunctive therapy to antidepressants in patients with major depressive
